Skip to main content

NCI Awards Integral Molecular $150K to ID Cancer Biomarkers

NEW YORK (GenomeWeb News) – Integral Molecular said today that the National Cancer Institute has awarded it a $150,000 contract to map epitopes for monoclonal antibodies directed against cancer biomarkers.

Integral, based in Philadelphia, will analyze protein targets of interest to the clinical cancer proteomics community using shotgun mutagenesis mapping technology to identify amino acids essential for antibody binding and to discover and characterize cancer-specific biomarkers.

During the first phase of the project, which is fully funded by NCI, Integral said it will epitope map antibodies generated against claudin membrane proteins involved in several types of cancer.

Shotgun mutagensis is a method for mapping epitopes by rapidly evaluating the effects of point mutations across an entire target protein. Using a patented high-throughput expression method, thousands of point mutations are simultaneously evaluated for functional protein activity, Integral said.

The approach is particular well-suited to cancer biomarkers, many of which are complex membrane proteins that are resistant to direct structural analysis, the company said.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.